U.S. markets closed
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow 30

    35,677.02
    +73.92 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Russell 2000

    2,291.27
    -4.91 (-0.21%)
     
  • Crude Oil

    83.98
    +0.22 (+0.26%)
     
  • Gold

    1,793.10
    -3.20 (-0.18%)
     
  • Silver

    24.39
    -0.06 (-0.24%)
     
  • EUR/USD

    1.1646
    +0.0015 (+0.13%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • GBP/USD

    1.3760
    -0.0035 (-0.25%)
     
  • USD/JPY

    113.5700
    -0.4180 (-0.37%)
     
  • BTC-USD

    60,559.65
    -502.94 (-0.82%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.25 (+0.34%)
     
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Coronavirus Latest: Friday, September 25

In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

On Friday, Novavax started its phase 3 coronavirus trial to test for safety and efficacy of its vaccine. This comes as AstraZeneca received partial immunity with the EU states saying that they will pay for part of the expenses if problems continue to arise with patients. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus.

Video Transcript

MYLES UDLAND: A busy week on developments as it relates to cases, as it relates to vaccine development. Anjalee Khemlani joins us now with the latest on all of that as we wrap up this week. Anjalee.

ANJALEE KHEMLANI: Thanks, Myles. Yep. So really one of the most interesting things to come out for the end of the week is Novavax, which is one of those earlier smaller biotechs that really got really into the race. And so now starting phase three in the UK, waiting to hear on when the start date is in the US, likely sometime in October, hopefully earlier in October. But no word yet on that.

And looking forward, you know, there's been a lot of discussion about the amount of federal funding that has gone into vaccine development and really what that means in terms of the taxpayer money and the liabilities there. Now, while vaccine makers in the US are indemnified against any liability of these vaccines that are being developed at really the fastest pace ever, in the UK and in Europe, that's not necessarily the practice. And so we heard that AstraZeneca has struck a deal with EU to do as much and sort of share that liability. And so that's a really interesting relationship that's happening there. AstraZeneca is looking at a low-cost option of the vaccine.

Meanwhile, another EU vaccine maker, Sanofi, is also going ahead with its-- with its trials. But they don't have the same protections, and they're going to be one of those that are more expensive offering on the market. We could compare that kind of to what Moderna and Pfizer, the two front runners in the US, are like, with Pfizer clearly stating that it hasn't relied on government funding, will be going forward with making a profit on the vaccine, and others kind of waiting to see where that all pans out. Myles.

MYLES UDLAND: All right, Anjalee. We will talk to you next week.